Treatment outcome of dogs with meticillin-resistant and meticillin-susceptible Staphylococcus pseudintermedius pyoderma

Veterinary Dermatology

Volumn 23, Issue 4, 2012, Pages

  Bryan, Jacqueline ^a   Frank, Linda A ^a   Rohrbach, Barton W ^a   Burgette, Laura J ^a   Cain, Christine L ^a   Bemis, David A ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLASSIFICATION; DOG; DRUG EFFECT; MICROBIOLOGY; PENICILLIN RESISTANCE; PYODERMA; RETROSPECTIVE STUDY; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; DOGS; METHICILLIN RESISTANCE; PYODERMA; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS;

CANIS FAMILIARIS; STAPHYLOCOCCUS; STAPHYLOCOCCUS PSEUDINTERMEDIUS;

EID: 84864130205     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/j.1365-3164.2012.01034.x     Document Type: Article

References (47)

1. Bannoehr J, Zakour NL, Waller AS et al. Population genetic structure of the Staphylococcus intermedius group: insights into agr diversification and the emergence of methicillin-resistant strains. J Bacteriol 2007; 189: 8685-8692.
2. Sasaki T, Kikuchi K, Tanaka Y et al. Methicillin-resistant Staphylococcus pseudintermedius in a veterinary teaching hospital. J Clin Microbiol 2007; 45: 1118-1125.
3. Biberstein EL, Jang SS, Hirsh DC. Species distribution of coagulase-positive staphylococci in animals. J Clin Microbiol 1984; 19: 610-615.
4. Scott DW, Miller WH, Griffin CE. Bacterial skin diseases. In: Muller and Kirk's Small Animal Dermatology. 6th edition. Philadelphia, PA: WB Saunders Co., 2001: 277-279.
5. Fitzgerald JR. The Staphylococcus intermedius group of bacterial pathogens: species re-classification, pathogenesis and the emergence of methicillin resistance. Vet Dermatol 2009; 20: 490-495.
6. Lloyd DH. Microbial diseases secondary to allergic skin disease - clinical significance and control. Eur J Companion Anim 2009; 19: 254-260.
7. Nuttall T, Williams N, Saunders R et al. Meticillin-resistant staphylococci in companion animals. Eur J Companion Anim 2008; 18: 280-286.
8. Jones RD, Kania SA, Rohrbach BW et al. Prevalence of oxacillin- and multidrug-resistant staphylococci in clinical samples from dogs: 1, 772 samples (2001-2005). J Am Vet Med Assoc 2007; 230: 221-227.
9. Kania SA, Williamson NL, Frank LA et al. Methicillin resistance of staphylococci isolated from the skin of dogs with pyoderma. Am J Vet Res 2004; 65: 1265-1268.
10. Chambers HF. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical applications. Clin Microbiol Rev 1997; 10: 781-791.
11. Descloux S, Rossano A, Perreten V. Characterization of new staphylococcal cassette chromosome mec (SCCmec) and topoisomerase genes in fluoroquinolone- and methicillin-resistant Staphylococcus pseudintermedius. J Clin Microbiol 2008; 46: 1818-1823.
12. Perreten V, Kadlec K, Schwarz S et al. Clonal spread of methicillin-resistant Staphylococcus pseudintermedius in Europe and North America: an international multicentre study. J Antimicrob Chemother 2010; 65: 1145-1154.
13. Huerta B, Maldonado A, Ginel PJ et al. Risk factors associated with the antimicrobial resistance of staphylococci in canine pyoderma. Vet Microbiol 2011; 150: 302-308.
14. Ganiere JP, Medaille C, Mangion C. Antimicrobial drug susceptibility of Staphylococcus intermedius clinical isolates from canine pyoderma. J Vet Med B Infect Dis Vet Public Health 2005; 52: 25-31.
15. Vanni M, Tognetti R, Pretti C et al. Antimicrobial susceptibility of Staphylococcus intermedius and Staphylococcus schleiferi isolated from dogs. Res Vet Sci 2009; 87: 192-195.
16. Yakuyama T, Namikawa K, Ichikawa Y et al. Antimicrobial drug susceptibility of Staphylococcus clinical isolates from canine pyoderma and external otitis. Jpn J Vet Dermatol 2008; 14: 135-137.
17. Bannerman TL, Peacock SJ. Staphylococcus, Micrococcus, and other catalase-positive cocci. In: Murray PR, Baron EJ, Jorgensen JH et al., eds. Manual of Clinical Microbiology. 9th edition. Washington, DC: ASM Press, 2007: 390-411.
18. Chanchaithong P, Prapasarakul N. Biochemical markers and protein pattern analysis for canine coagulase-positive staphylococci and their distribution on dog skin. J Microbiol Methods 2011; 86: 175-181.
19. Clinical and Laboratory Standards Institute (CLSI). Performance Standard for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals; Approved Standard - 3rd edition. CLSI Document M31-A3. Wayne, PA: CLSI, 2008.
20. Papich MG. Proposed changes to Clinical Laboratory Standards Institute interpretation criteria for methicillin-resistant Staphylococcus pseudintermedius isolated from dogs. J Vet Diagn Invest 2010; 22: 160.
21. Frank LA, Kania SA, Kirzeder EM et al. Risk of colonization or gene transfer to owners of dogs with meticillin-resistant Staphylococcus pseudintermedius. Vet Dermatol 2009; 20: 496-501.
22. Frank LA, Kirzeder EM, Davis JA et al. Nisin impregnated wipes for the treatment of canine pyoderma and surface bacterial colonization. Proceedings of the North American Veterinary Dermatology Forum. Vet Dermatol 2009; 20: 219 (Abstract).
23. Bemis DA, Jones RD, Frank LA et al. Evaluation of susceptibility test breakpoints used to predict mecA-mediated resistance in Staphylococcus pseudintermedius isolated from dogs. J Vet Diagn Invest 2009; 21: 53-58.
24. Loeffler A, Linek M, Moodley A et al. First report of multiresistant, mecA-positive Staphylococcus intermedius in Europe: 12 cases from a veterinary dermatology referral clinic in Germany. Vet Dermatol 2007; 18: 412-421.
25. Nienhoff U, Kadlec K, Chaberny IF et al. Methicillin-resistant Staphylococcus pseudintermedius among dogs admitted to a small animal hospital. Vet Microbiol 2011; 150: 191-197.
26. Yoon JW, Lee KJ, Lee SY et al. Antibiotic resistance profiles of Staphylococcus pseudintermedius isolates from canine patients in Korea. J Microbiol Biotechnol 2010; 20: 1764-1768.
27. Greene CE. Antimicrobial drug formulary. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 3rd edition. Philadelphia, PA: W.B. Saunders Co., 2006: 1186-1333.
28. Watson A. Chloramphenicol 2. Clinical pharmacology in dogs and cats. Aust Vet J 1991; 68: 2-5.
29. Ramilo O, Kinane BT, McCracken GH. Chloramphenicol neurotoxicity. Pediatr Infect Dis J 1988; 7: 358-359.
30. Tateishi J. Comparative study of neurotoxicity of clioqionol, ethambutol, isoniazid, and chloramphenicol in dogs. Folia Psychiatr Neurol Jpn 1974; 28: 11-17.
31. Epstein ME, Amodio-Groton M, Sadick NS. Antimicrobial agents for the dermatologist. II. Macrolides, fluoroquinolones, rifamycins, tetracyclines, trimethoprim-sulfamethoxazole, and clindamycin. J Am Acad Dermatol 1997; 37: 365-381.
32. Frank LA. Clinical pharmacology of rifampin. J Am Vet Med Assoc 1990; 197: 114-117.
33. Sentürk S, Özel E, Sen A. Clinical efficacy of rifampicin for treatment of canine pyoderma. Acta Vet Brno 2005; 74: 117-122.
34. Koch HJ, Vercelli A. Shampoos and other topical therapies. In: Ihrke PJ, Mason IS, White SD, eds. Advances in Veterinary Dermatology, volume 2. New York: Pergamon Press, 1993: 409-411.
35. Loeffler A, Cobb MA, Bond R. Comparison of a chlorhexidine and a benzoyl peroxide shampoo as sole treatment in canine superficial pyoderma. Vet Record 2011; 169: 249-253.
36. de Jaham C. Effects of an ethyl lactate shampoo in conjunction with a systemic antibiotic in the treatment of canine superficial bacterial pyoderma in an open-label, nonplacebo-controlled study. Vet Therapeut 2003; 4: 94-100.
37. Loeffler A, Baines SJ, Toleman MS et al. In vitro activity of fusidic acid and mupirocin against coagulase-positive staphylococci from pets. J Antimicrob Chemother 2008; 62: 1301-1304.
38. Murayama N, Nagata M, Terada Y et al. Efficacy of a surgical scrub including 2% chlorhexidine acetate for canine superficial pyoderma. Vet Dermatol 2010; 21: 586-592.
39. Young R, Buckley L, McEwan N et al. Comparative in vitro efficacy of antimicrobial shampoos: a pilot study. Vet Dermatol 2012; 23: 36-e8.
40. Fazakerley J, Williams N, Carter S et al. Heterogeneity of Staphylococcus pseudintermedius isolates from atopic and healthy dogs. Vet Dermatol 2010; 21: 578-585.
41. Fazakerley J, Nuttall T, Sales D et al. Staphylococcal colonization of mucosal and lesional skin sites in atopic and healthy dogs. Vet Dermatol 2009; 20: 179-184.
42. Pressler B. Immunosuppressive drugs: beyond glucocorticoids. Vet Med 2010; 105: 364-371.
43. Scott DW, Miller WH, Griffin CE. Dermatologic therapy. In: Muller and Kirk's Small Animal Dermatology. 6th edition. Philadelphia, PA: WB Saunders Co., 2001: 244-252.
44. Ettinger SJ, Feldman EC. Glucocorticoid therapy. In: Textbook of Veterinary Internal Medicine. 6th ed. Amsterdam: Elsevier Saunders, 2005: 503-508.
45. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-1723.
46. Schwartz BS, Graber CJ, Diep BA et al. Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300. Clin Infect Dis 2009; 48: 1483-1484.
47. Trzcinski K, Cooper BS, Hryniewicz W et al. Expression of resistance to tetracyclines in strains of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2000; 45: 763-770.